Condition: Primary Open Angle Glaucoma · Sponsor: Alcon Research
The purpose of this post-approval study is to evaluate the rate of Hydrus Microstent malposition and associated clinical sequelae occurring within 24 months post-operation. Qualified subjects will undergo uncomplicated cataract surgery with placement of a monofocal intraocular lens (IOL), followed by implantation of the Hydrus Microstent.
This description comes directly from the study's public registry record.
Alcon Call Center · 1-888-451-3937 · alcon.medinfo@alcon.com
Always discuss trial participation with your own doctor first.
| Coastal Vision | Irvine, California, United States | Completed |
| Sacramento Eye Consultants | Sacramento, California, United States | Recruiting |
| Eye Center of Northern Colorado | Loveland, Colorado, United States | Recruiting |
| Jones Eye Center PC | Sioux City, Iowa, United States | Recruiting |
| Stiles Eyecare Excellence Cataracts and Glaucoma | Overland Park, Kansas, United States | Not Yet Recruiting |
| Visionary Eye Doctors | Rockville, Maryland, United States | Not Yet Recruiting |
| Fraser Eye Care Center | Fraser, Michigan, United States | Recruiting |
| Twin Cities Eye Consultants | Coon Rapids, Minnesota, United States | Recruiting |
| Midwest Vision Research Foundation | Chesterfield, Missouri, United States | Recruiting |
| Moyes Eye Center | Kansas City, Missouri, United States | Not Yet Recruiting |
| Center for Sight | Las Vegas, Nevada, United States | Recruiting |
| Carolina Eye Associates PA | Southern Pines, North Carolina, United States | Recruiting |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04553523